Search Results

You are looking at 261 - 270 of 1,601 items for :

  • "characteristics" x
  • Refine by Access: All x
Clear All
Full access

Nonoperative Treatment of Large (5–7 cm), Node-Negative Non–Small Cell Lung Cancer Commonly Deviates From NCCN Guidelines

Craig S. Schneider, Robert A. Oster, Aparna Hegde, Michael C. Dobelbower, John M. Stahl, and Adam J. Kole

chemotherapy. Most patients received CFRT (64.3%), whereas SBRT (21.8%) and HFRT (13.9%) were less common. The most commonly used RT fractionation regimen for each category can be found in supplemental eTable 1 . Table 1. Patient Characteristics

Full access

New Therapies for Ovarian Cancer

Deborah K. Armstrong

patients receive chemotherapy with paclitaxel and carboplatin. In early-stage nonserous epithelial ovarian cancer, 3 cycles have been shown to be as effective as 6 Figure 1. Characteristics of ovarian cancer subtypes. Abbreviation: MP

Full access

Clinicopathologic Features, Treatment Response, and Outcomes of Immune Checkpoint Inhibitor–Related Esophagitis

Kavea Panneerselvam, Rajan N. Amin, Dongguang Wei, Dongfeng Tan, Phillip J. Lum, Hao Chi Zhang, David M. Richards, Mehmet Altan, Petros Grivas, John A. Thompson, Anusha S. Thomas, and Yinghong Wang

knowledge regarding the typical characteristics of ICI-related esophagitis and the appropriate treatments for this condition. In this retrospective study, we aimed to characterize esophagitis associated with the use of ICIs and describe its clinical

Full access

Uptake of the 21-Gene Assay Among Women With Node-Positive, Hormone Receptor−Positive Breast Cancer

Megan C. Roberts, Allison W. Kurian, and Valentina I. Petkov

, including race, SES, and age, given the need to more deeply characterize test uptake in these groups over time. Population characteristics were analyzed using chi-square tests. Among those who received the 21-gene assay, kernel density estimates of the RS

Full access

Incident Cancer Detection During the COVID-19 Pandemic

Antoine Eskander, Qing Li, Jiayue Yu, Julie Hallet, Natalie G. Coburn, Anna Dare, Kelvin K.W. Chan, Simron Singh, Ambica Parmar, Craig C. Earle, Lauren Lapointe-Shaw, Monika K. Krzyzanowska, Timothy P. Hanna, Antonio Finelli, Alexander V. Louie, Nicole Look Hong, Jonathan C. Irish, Ian J. Witterick, Alyson Mahar, Christopher W. Noel, David R. Urbach, Daniel I. McIsaac, Danny Enepekides, and Rinku Sutradhar

. Data Sources The analysis was performed using data held at the ICES (previously known as the Institute for Clinical Evaluative Sciences). Demographic characteristics, vital status, and date of death for all individuals covered under the Ontario Health

Full access

Multiorgan Immune-Related Adverse Events During Treatment With Atezolizumab

Ganessan Kichenadasse, John O. Miners, Arduino A. Mangoni, Andrew Rowland, Ashley M. Hopkins, and Michael J. Sorich

outcomes. Baseline age, sex, race, tumor characteristics, serum lactate dehydrogenase and C-reactive protein (CRP) levels, lung immune prognostic index (LIPI), neutrophil-to-lymphocyte ratio, and various subpopulations of white cells were evaluated for

Full access

Allogeneic Stem Cell Transplantation for Philadelphia Chromosome–Positive Acute Myeloid Leukemia

Vijaya Raj Bhatt, Mojtaba Akhtari, R. Gregory Bociek, Jennifer N. Sanmann, Ji Yuan, Bhavana J. Dave, Warren G. Sanger, Anne Kessinger, and James O. Armitage

distinguish between the entities. 4 Clinical characteristics might also be helpful in making the distinction, including no history of CML or myeloproliferative disorder, no evidence of chronic or accelerated phases of CML after induction therapy, and no

Full access

Outcomes of a Dietary Intervention to Reduce Bladder Cancer Recurrence and Progression in Survivors of Non–Muscle-Invasive Bladder Cancer

Karen H. Kim Yeary, Han Yu, Margaret Gates Kuliszewski, Qiang Li, Susan E. McCann, Rachel Pratt, Frances G. Saad-Harfouche, Zinian Wang, Nikia Clark, Chong Wang, Elizabeth DiCarlo, and Li Tang

(NMIBC). NMIBC can be removed; however, up to 50% to 80% of NMIBC recurs within 5 years, with some patients experiencing progression to muscle-invasive disease with poor survival. 3 – 5 Depending on pathologic characteristics, patients with high

Full access

How to Choose An Appropriate Anticoagulant for Cancer-Associated Thrombosis

Jordan K. Schaefer, Amro Elshoury, Victoria R. Nachar, Michael B. Streiff, and Ming Y. Lim

General Anticoagulant Characteristics Anticoagulants recommended in current CAT treatment guidelines include low-molecular-weight heparin (LMWH), warfarin, and in recent years, the direct oral anticoagulants (DOACs). 4 Fondaparinux is also occasionally

Full access

Compliance With NCCN Guidelines for Evaluation and Treatment of Anemia Among Patients With Solid Tumors

Demetra Hypatia Hufnagel, Lia Manfredi Bos, Alaina Johnson Brown, and Lauren Shore Prescott

Characteristics A total of 25,018 patients met the inclusion criteria ( Table 1 ). Median age at diagnosis was 60 years (IQR, 51–68 years), and most patients were White (88%) and of non-Hispanic ethnicity (95%). The most common malignancies were respiratory tract